Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer

Gynecologic Oncology

Volumn 94, Issue 3, 2004, Pages 685-692

  Katsaros, D ^a   Cho, W ^b   Singal, R ^c   Fracchioli, S ^a   Rigault De La Longrais, I A ^a   Arisio, R ^a   Massobrio, M ^a   Smith, M ^c   Zheng, W ^b   Glass, J ^c   Yu, H ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b YALE CANCER CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Epithelial ovarian cancer; Methylation; p16

Indexed keywords

BISULFITE; PROTEIN P16;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DNA EXTRACTION; FEMALE; FOLLOW UP; GENE FUNCTION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; METHYLATION; MORTALITY; OVARY; OVARY CANCER; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RISK ASSESSMENT; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TISSUE SECTION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; GENES, P16; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; PROMOTER REGIONS (GENETICS);

EID: 4444284167     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.06.018     Document Type: Article

References (39)

1. Shapiro G.I., Rollins B.J. p16INK4A as a human tumor suppressor. Biochim. Biophys. Acta. 1242(3):1996 (Mar. 18);165-169
2. Liggett W.H. Jr., Sidransky D. Role of the p16 tumor suppressor gene in cancer. J. Clin. Oncol. 16(3):1998 (Mar.);1197-1206
3. Serrano M. The INK4a/ARF locus in murine tumorigenesis. Carcinogenesis. 21(5):2000 (May);865-869
4. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366(6456):1993 (Dec. 16);704-707
5. Rocco J.W., Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp. Cell Res. 264(1):2001 (Mar. 10);42-55
6. Shapiro G.I., Park J.E., Edwards C.D., Mao L., Merlo A., Sidransky D., et al. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res. 55(24):1995 Dec 15;6200-6209
7. Singal R., Ginder G.D. DNA methylation. Blood. 93(12):1999 (Jun. 15);4059-4070
8. Karpf A.R., Jones D.A. Reactivating the expression of methylation silenced genes in human cancer. Oncogene. 21(35):2002 Aug 12;5496-5503
9. Marchini S., Codegoni A.M., Bonazzi C., Chiari S., Broggini M. Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours. Br. J. Cancer. 76(2):1997;146-149
10. Kusume T., Tsuda H., Kawabata M., Inoue T., Umesaki N., Suzuki T., et al. The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin. Cancer Res. 5(12):1999 (Dec.);4152-4157
11. Sui L., Dong Y., Ohno M., Goto M., Inohara T., Sugimoto K., et al. Inverse expression of Cdk4 and p16 in epithelial ovarian tumors. Gynecol. Oncol. 79(2):2000 (Nov.);230-237
12. Havrilesky L.J., Alvarez A.A., Whitaker R.S., Marks J.R., Berchuck A. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. Gynecol. Oncol. 83(3):2001 (Dec.);491-500
13. Kudoh K., Ichikawa Y., Yoshida S., Hirai M., Kikuchi Y., Nagata I., et al. Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer. Int. J. Cancer. 99(4):2002 (Jun. 1);579-582
14. Wolf J.K., Mills G.B., Bazzet L., Bast R.C. Jr., Roth J.A., Gershenson D.M. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol. Oncol. 75(2):1999 (Nov.);261-266
15. Partridge E.E., Barnes M.N. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J. Clin. 49:1999;297-320
16. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer Statistics, 2003 CA. Cancer J. Clin. 53:2003;5-26
17. Rustin G.J., Nelstrop A.E., Tuxen M.K., Lambert H.E. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann. Oncol. 7(4):1996 Apr;361-364
18. International Federation of Gynecology and Obstetrics Changes in definition of clinical staging for carcinoma of the cervix and ovary. Am. J. Obstet. Gynecol. 56:1987;263-264
19. Serov S.F., Soully R.F., Sobin L.H. Histological typing of ovarian tumors. International Histological Classification of Tumors. 1973;37-42 World Health Organization, Geneva
20. Singal R., Ferris R., Little J.A., Wang S.Z., Ginder G.D. Methylation of the minimal promoter of an embryonic globin gene silences transcription in primary erythroid cells. Proc. Natl. Acad. Sci. U.S.A. 94(25):1997 (Dec. 9);13724-13729
21. Cairns P., Mao L., Merlo A., Lee D.J., Schwab D., Eby Y., et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science. 265(5170):1994 (Jul. 15);415-417
22. Herman J.G., Merlo A., Mao L., Lapidus R.G., Issa J.P., Davidson N.E., et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55(20):1995 Oct 15;4525-4530
23. Gonzalez-Zulueta M., Bender C.M., Yang A.S., Nguyen T., Beart R.W., Van Tornout J.M., et al. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55(20):1995 Oct 15;4531-4535
24. Shih Y.C., Kerr J., Liu J., Hurst T., Khoo S.K., Ward B., et al. Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours. Int. J. Cancer. 70(5):1997 (Mar. 4);508-511
25. Ryan A., Al-Jehani R.M., Mulligan K.T., Jacobs I.J. No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis. Gynecol. Oncol. 68(1):1998 (Jan.);14-17
26. Niederacher D., Yan H.Y., An H.X., Bender H.G., Beckmann M.W. CDKN2A gene inactivation in epithelial sporadic ovarian cancer. Br. J. Cancer. 80(12):1999 (Aug.);1920-1926
27. Milde-Langosch K., Ocon E., Becker G., Loning T. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int. J. Cancer. 79(1):1998 (Feb. 20);61-65
28. Wong Y.F., Chung T.K., Cheung T.H., Nobori T., Yu A.L., Yu J., et al. Methylation of p16INK4A in primary gynecologic malignancy. Cancer Lett. 136(2):1999 Mar 1;231-235
29. McCluskey L.L., Chen C., Delgadillo E., Felix J.C., Muderspach L.I., Dubeau L. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. Gynecol. Oncol. 72(1):1999 (Jan.);87-92
30. Jimenez E., Garcia-Foncillas J., Salgado E., Okroujnov I., Angeletti S., Huarriz M., et al. Methylation status assay of p16 and p15 promoters by methylation-specific PCR in epithelial ovarian cancer. Proc. Am. Assoc. Cancer Res. 40:1999;2913
31. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1(7):1995 (Jul.);686-692
32. Gonzalez-Zulueta M., Bender C.M., Yang A.S., Nguyen T., Beart R.W., Van Tornout J.M., et al. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55(20):1995 (Oct. 15);4531-4535
33. Otterson G.A., Khleif S.N., Chen W., Coxon A.B., Kaye F.J. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine. Oncogene. 11(6):1995 (Sep. 21);1211-1216
34. Wiencke J.K., Zheng S., Lafuente A., Lafuente M.J., Grudzen C., Wrensch M.R., et al. Aberrant methylation of p16INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 8(6):1999 (Jun.);501-506
35. Esteller M., Gonzalez S., Risques R.A., Marcuello E., Mangues R., Germa J.R., et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J. Clin. Oncol. 19(2):2001 (Jan. 15);299-304
36. Modesitt S.C., Ramirez P., Zu Z., Bodurka-Bevers D., Gershenson D., Wolf J.K. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin. Cancer Res. 7(6):2001 (Jun.);1765-1772
37. Wang M., Wei J., Zhang J. Replacement of the p16 gene in human ovarian cancer cells. Chin. Med. J. (Engl.). 114(8):2001 (Aug.);857-859
38. Kawakami Y., Hama S., Hiura M., Nogawa T., Chiba T., Yokoyama T., et al. Adenovirus-mediated p16 gene transfer changes the sensitivity to taxanes and Vinca alkaloids of human ovarian cancer cells. Anticancer Res. 21(4A):2001 (Jul.-Aug.);2537-2545
39. Ha T.U., Segev D.L., Barbie D., Masiakos P.T., Tran T.T., Dombkowski D., et al. Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism. J. Biol. Chem. 275(47):2000 (Nov. 24);37101-37109